• FirefoxUpgrade to the new Firefox »
  •  Dow Up0.03% Nasdaq Up0.29%

    Genomic Health Inc. (GHDX)

    32.69 Up 1.37(4.37%) Jan 26, 4:00PM EST
    Add to Portfolio
    ProfileGet Profile for:
    Genomic Health Inc.
    301 Penobscot Drive
    Redwood City, CA 94063
    United States - Map
    Phone: 650-556-9300
    Website: http://www.genomichealth.com

    Index Membership:N/A
    Industry:Medical Laboratories & Research
    Full Time Employees:684

    Business Summary 

    Genomic Health, Inc., a healthcare company, provides actionable genomic information to personalize cancer treatment decisions in the United States and internationally. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, facilitating physicians and patients to make individualized treatment decisions. The company offers the Oncotype DX invasive breast cancer test that is used for early stage invasive breast cancer patients to predict the likelihood of breast cancer recurrence and the likelihood of chemotherapy benefit. It also provides the Oncotype DX colon cancer test, which is used to predict the likelihood of colon cancer recurrence in patients with stage II disease, as well as for use in patients with stage III disease treated with oxaliplatin-containing adjuvant therapy. In addition, the company provides the Oncotype DX tests for patients with ductal carcinoma in situ, a pre-invasive form of breast cancer; and Oncotype DX prostate cancer test, which provides a genomic prostate score to predict disease aggressiveness in men with low risk disease, as well as is used to enhance treatment decisions for prostate cancer patients in conjunction with the Gleason score or tumor grading. Genomic Health, Inc. was founded in 2000 and is based in Redwood City, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Genomic Health Inc.

    Corporate Governance 
    Genomic Health Inc.’s ISS Governance QuickScore as of Jan 1, 2015 is 7. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 5; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Ms. Kimberly J. Popovits , 56
    Chairman of The Board, Chief Exec. Officer, Pres and Member of Non-Management Stock Option Committee
    Mr. G. Bradley Cole , 59
    Chief Financial Officer, Chief Operating Officer, Principal Accounting Officer, Sec. and Member of Non-Management Stock Option Committee
    Dr. Steven Shak M.D., 64
    Exec. VP of R&D
    Dr. Paul Aldridge Ph.D.,
    Sr. VP and Chief Information officer
    Mr. James J. Vaughn R.Ph., 51
    Sr. VP of Worldwide Commercial
    Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders